Lowering LDL Early: Preventing Heart Disease & Alzheimer's, APOE4 and More
Cardiologist and lipidologist Dr. Michael Davidson joins Peter Attia to make the case for lowering LDL cholesterol as early in life as possible. They trace the decades-long story of CETP inhibitors — from repeated failures to the more potent obicetrapib — and explore its promise for cardiovascular disease, metabolic health, and Alzheimer's prevention in APOE4 carriers.
Overview
In this in-person conversation, Peter Attia sits down with cardiologist and lipidologist Dr. Michael Davidson, who runs the lipid clinic at the University of Chicago and leads New Amsterdam Pharmaceuticals. Driven by his own family history of early heart disease, Davidson argues for primordial prevention — stopping plaque before it forms by lowering LDL as early in life as possible.
The pair trace the long, humbling history of CETP inhibitors, a class once chased for raising HDL that failed repeatedly until Merck's REVEAL trial proved LDL lowering through CETP delivers real cardiovascular benefit. They turn to obicetrapib, a far more potent CETP inhibitor now in large outcome trials, and its effects on LDL, Lp(a), small particles, and diabetes risk. The most intriguing frontier is Alzheimer's disease: Davidson explains how APOE4 disrupts the brain's cholesterol metabolism and why raising HDL-like particles might help, supported by early biomarker data in APOE4 carriers.
The discussion also covers the nuances of ApoB versus LDL-P, the case against very high statin doses, and the promise and limits of blood biomarkers like p-tau217. They close with the science of DHA and the blood-brain barrier, the potential of AI to speed clinical trials, and the experimental protein klotho. Throughout, the tone is one of cautious optimism grounded in decades of hard-won trial data.
Key quotes
5If you keep your LDL below 80 throughout your lifetime, you don't get heart disease.
The time to quit smoking is before you start. And if you've already started, the time to quit smoking is today.
It goes from an empty garbage truck to a loaded garbage truck.
Alzheimer's is not a disease of old age. It's a disease of middle age that presents in old age.
The goal of science is not to fool yourself, and you're the easiest person to fool.
Key ideas
8The 8-gram rule
Davidson frames lifelong cholesterol exposure as roughly 8 grams accumulating before heart disease appears. Keeping LDL low across decades — not just within a 10-year window — is what prevents plaque from forming.
LDL is causal, so treat it like one
Because LDL is causally linked to atherosclerosis — like smoking to cancer — the argument shifts from short-term risk scores to treating the underlying driver. The time to address a causal factor is as early as possible.
How CETP inhibition works
CETP transfers cholesterol from HDL to LDL; blocking it raises HDL, lowers LDL, and funnels cholesterol out through the intestine. Animals that naturally lack CETP tend to resist atherosclerosis.
The HDL hypothesis collapses
Raising HDL was once seen as the holy grail, but torcetrapib, dalcetrapib, and evacetrapib all failed on events. Later genetic studies showed that pure HDL-raising offers no protection on its own.
REVEAL rescues the target
Merck's 30,000-patient anacetrapib trial showed a 17% LDL reduction produced a 9% event reduction, proving that CETP-driven LDL lowering translates into real cardiovascular benefit even though the drug itself never launched.
APOE4 and the brain's cholesterol problem
The brain runs its own cholesterol economy behind the blood-brain barrier. APOE4 impairs cholesterol clearance from neurons, setting up the inflammatory, amyloid, and tau cascade that underlies Alzheimer's.
p-tau217 as an early signal
Blood biomarkers like p-tau217 predict brain amyloid almost as well as PET scans. In obicetrapib's data, APOE4 homozygotes showed a striking improvement across tau and amyloid markers.
DHA needs the right carrier
DHA crosses into the brain mainly in its lysoPC form via the MFSD2A transporter. Standard fish oil supports the heart but may not reach the brain — lysoPC DHA supplements are on the horizon.
Practical takeaways
6- 1
Start thinking about LDL decades early 6:00
The 30-to-40 window is when plaque forms fastest; the earlier LDL is managed, the greater the lifelong protection. This is a conversation to have with your clinician, not a self-prescription.
- 2
Don't let a high HDL reassure you 45:00
A high good-cholesterol number does not guarantee low risk; dysfunctional HDL and genetic variants can coexist with significant plaque. Imaging can reveal hidden disease.
- 3
Question very high statin doses 1:07:00
Most of a statin's benefit comes at the lower end of its dose range; combination therapy can reach the same LDL lowering with fewer side effects — worth raising with your doctor.
- 4
The net benefit of statins still favors most patients 2:01:00
The small increase in diabetes risk is far outweighed by the cardiovascular benefit; lower doses plus combination therapy can reduce that tradeoff.
- 5
Knowing your APOE4 status can motivate action 2:15:00
If you carry APOE4, lifestyle, exercise, blood pressure and glucose control, and avoiding smoking all matter — knowledge can drive the hard choices best made early in life.
- 6
Mind the difference between heart and brain omega-3s 1:49:00
Eating fatty fish or a quality EPA/DHA supplement supports cardiovascular health, but getting DHA into the brain likely requires the emerging lysoPC form.
Topics & chapters
15Introduction & Dr. Davidson's path to lipidology
Davidson shares how his father's death at 47 and his own abnormal lipids set him on a lifelong path in prevention and lipid research.
Primordial prevention and the 8-gram rule
Why stopping plaque before it forms beats reversing it, and the idea that keeping LDL below 80 for life largely prevents heart disease.
LDL as a causal driver: the smoking analogy
Attia and Davidson reframe prevention around causality, comparing LDL to smoking, hypertension, and diabetes.
CETP inhibition explained
What cholesteryl ester transfer protein does, and why blocking it raises HDL and lowers LDL across mammals.
The HDL hypothesis and its early failures
The reverse-cholesterol-transport story and how torcetrapib's off-target effects ended the first CETP drug in disappointment.
Anacetrapib (REVEAL): validating the target
Merck's large trial confirmed that lowering LDL through CETP inhibition produces a cardiovascular benefit, rescuing the whole class.
Obicetrapib's origins and early data
How New Amsterdam acquired the drug, the TULIP study, and why obicetrapib is far more potent at a much lower dose.
When high HDL is not protective
Genetic studies show pure HDL-raising offers no protection, and high HDL from SRB1 or alcohol can even raise risk.
The obicetrapib trial program
ROSE, BROOKLYN, BROADWAY, and TANDEM data, plus the ongoing PREVAIL outcome trial in secondary prevention.
ApoB vs LDL-P discordance
Why these particle measures can diverge, the role of insulin resistance, and what CETP inhibition does to small particles.
Lp(a) lowering and fitting obicetrapib with statins
The roughly 50% Lp(a) reduction and why obicetrapib could become the go-to companion drug after statins.
Statin tradeoffs and drug pricing
High-dose statins, liver enzymes, and a frank discussion of how pricing and access shape whether patients get new drugs.
APOE4, brain cholesterol, and the Alzheimer's hypothesis
How the brain manages cholesterol behind the blood-brain barrier and why APOE4 disrupts it, driving the Alzheimer's cascade.
Alzheimer's biomarkers and the road ahead
p-tau217 and related markers, the promise and limits of surrogates, and plans for a prevention-focused trial.
DHA, the blood-brain barrier, omega-3s, AI, and klotho
Why DHA needs the lysoPC form to reach the brain, how AI might speed trials, and the experimental protein klotho, before closing advice for APOE4 carriers.